250 related articles for article (PubMed ID: 31222647)
1. Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones.
Castiglione V; Pottel H; Lieske JC; Lukas P; Cavalier E; Delanaye P; Rule AD
J Nephrol; 2020 Feb; 33(1):101-107. PubMed ID: 31222647
[TBL] [Abstract][Full Text] [Related]
2. Risk of ESRD and Mortality in Kidney and Bladder Stone Formers.
Dhondup T; Kittanamongkolchai W; Vaughan LE; Mehta RA; Chhina JK; Enders FT; Hickson LJ; Lieske JC; Rule AD
Am J Kidney Dis; 2018 Dec; 72(6):790-797. PubMed ID: 30146423
[TBL] [Abstract][Full Text] [Related]
3. Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review.
Roumeliotis S; Dounousi E; Eleftheriadis T; Liakopoulos V
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717170
[TBL] [Abstract][Full Text] [Related]
4. Dietary Risk Factors for Incident and Recurrent Symptomatic Kidney Stones.
Chewcharat A; Thongprayoon C; Vaughan LE; Mehta RA; Schulte PJ; O'Connor HM; Lieske JC; Taylor EN; Rule AD
Mayo Clin Proc; 2022 Aug; 97(8):1437-1448. PubMed ID: 35933132
[TBL] [Abstract][Full Text] [Related]
5. Vascular calcification and bone mineral density in recurrent kidney stone formers.
Shavit L; Girfoglio D; Vijay V; Goldsmith D; Ferraro PM; Moochhala SH; Unwin R
Clin J Am Soc Nephrol; 2015 Feb; 10(2):278-85. PubMed ID: 25635036
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix Gla protein and bone morphogenetic protein 2 in renal papillary tissues in patients with calcium oxalate kidney stones].
Zhu M; Zeng F; Cui Y; Liu X; Chen H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 42(3):277-283. PubMed ID: 28364100
[TBL] [Abstract][Full Text] [Related]
7. Increased Dephospho-uncarboxylated Matrix Gla-Protein Is Associated With Lower Axial Skeletal Muscle Mass in Patients With Hypertension.
Vidula MK; Akers S; Ansari BA; Kim J; Kumar AA; Tamvada D; Satija V; Mohan-Rao Vanjarapu J; Jehangir Q; Magro C; Qian C; Chirinos JA
Am J Hypertens; 2022 May; 35(5):393-396. PubMed ID: 35511478
[TBL] [Abstract][Full Text] [Related]
8. Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers.
Kittanamongkolchai W; Mara KC; Mehta RA; Vaughan LE; Denic A; Knoedler JJ; Enders FT; Lieske JC; Rule AD
Clin J Am Soc Nephrol; 2017 Mar; 12(3):476-482. PubMed ID: 28148559
[TBL] [Abstract][Full Text] [Related]
9. Kidney Function After the First Kidney Stone Event.
Haley WE; Enders FT; Vaughan LE; Mehta RA; Thoman ME; Vrtiska TJ; Krambeck AE; Lieske JC; Rule AD
Mayo Clin Proc; 2016 Dec; 91(12):1744-1752. PubMed ID: 27776839
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes.
Vaughan LE; Enders FT; Lieske JC; Pais VM; Rivera ME; Mehta RA; Vrtiska TJ; Rule AD
Mayo Clin Proc; 2019 Feb; 94(2):202-210. PubMed ID: 30527866
[TBL] [Abstract][Full Text] [Related]
11. Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation.
Xu LHR; Adams-Huet B; Poindexter JR; Maalouf NM; Moe OW; Sakhaee K
J Urol; 2017 Jun; 197(6):1465-1471. PubMed ID: 28111301
[TBL] [Abstract][Full Text] [Related]
12. The Association Between 24-Hour Urine and Stone Recurrence Among High Risk Kidney Stone Formers: A Population Level Assessment.
Samson PC; Holt SK; Hsi RS; Sorensen MD; Harper JD
Urology; 2020 Oct; 144():71-76. PubMed ID: 32540303
[TBL] [Abstract][Full Text] [Related]
13. Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community.
Singh P; Enders FT; Vaughan LE; Bergstralh EJ; Knoedler JJ; Krambeck AE; Lieske JC; Rule AD
Mayo Clin Proc; 2015 Oct; 90(10):1356-65. PubMed ID: 26349951
[TBL] [Abstract][Full Text] [Related]
14. Stone formation in patients less than 20 years of age is associated with higher rates of stone recurrence: Results from the Registry for Stones of the Kidney and Ureter (ReSKU).
Li Y; Bayne D; Wiener S; Ahn J; Stoller M; Chi T
J Pediatr Urol; 2020 Jun; 16(3):373.e1-373.e6. PubMed ID: 32280060
[TBL] [Abstract][Full Text] [Related]
15. Re: Evaluation of Inactive Matrix-Gla-Protein (MGP) as a Biomarker for Incident and Recurrent Kidney Stones.
Assimos DG
J Urol; 2019 Dec; 202(6):1092. PubMed ID: 31532295
[No Abstract] [Full Text] [Related]
16. Vitamin D status in patients with recurrent kidney stones.
Pipili C; Oreopoulos DG
Nephron Clin Pract; 2012; 122(3-4):134-8. PubMed ID: 23712072
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism of matrix Gla protein gene is associated with kidney stones.
Gao B; Yasui T; Itoh Y; Tozawa K; Hayashi Y; Kohri K
J Urol; 2007 Jun; 177(6):2361-5. PubMed ID: 17509359
[TBL] [Abstract][Full Text] [Related]
18. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population.
Lu X; Gao B; Liu Z; Tian X; Mao X; Emmanuel N; Zhu Q; Xiao C
Gene; 2012 Dec; 511(2):127-30. PubMed ID: 23046575
[TBL] [Abstract][Full Text] [Related]
19. Intestinal oxalate and calcium absorption in recurrent renal stone formers and healthy subjects.
Lindsjö M; Danielson BG; Fellström B; Ljunghall S
Scand J Urol Nephrol; 1989; 23(1):55-9. PubMed ID: 2922580
[TBL] [Abstract][Full Text] [Related]
20. Changes in urinary risk profile after short-term low sodium and low calcium diet in recurrent Swiss kidney stone formers.
Seeger H; Kaelin A; Ferraro PM; Weber D; Jaeger P; Ambuehl P; Robertson WG; Unwin R; Wagner CA; Mohebbi N
BMC Nephrol; 2017 Dec; 18(1):349. PubMed ID: 29202723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
